News
Colorado Says Yes to Medical Use of ‘Magic Mushrooms’
Colorado voters approved a measure to make the medical use of 'magic mushrooms' legal, paving the way for its use in treating several mental health disorders
Your search for psilocybin returned 16 results
News
Psilocybin + Psychotherapy Cuts Heavy Drinking Days in Alcoholism
Percentage of heavy drinking days reduced with psilocybin combined with psychotherapy versus active placebo plus psychotherapy
MPR Weekly Dose Podcast
MPR Weekly Dose Podcast Episode 100
This week Pfizer seeks Emergency Use Authorization for their COVID-19 oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.
News
Psychedelic Drug Shows Promise in Treatment-Resistant Depression
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I drug in the US.
News
Psilocybin Compared With Escitalopram for Depression
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram
News, Psychiatric Disorders
Benefits of Psilocybin-Assisted Psychotherapy May Be Lasting
Reductions in anxiety, depression in cancer-related psychiatric distress sustained at 3.2 and 4.5 years.
Drugs in the Pipeline
Psilocybin Designated Breakthrough Tx for Major Depressive Disorder
The FDA has granted Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder.
Drugs in the Pipeline
Psilocybin Gets Breakthrough Tx Designation for Treatment-Resistant Depression
The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.
News
Researchers Recommend Reclassification of Psilocybin
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.
Drugs in the Pipeline
Psilocybin Study Gets Green Light From FDA for Treatment-Resistant Depression
The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.
